05Nov/24

How Much Do We Really Know About Antibody-Drug Conjugates (ADCs): A New Way To Kill Cancer?

November 5, 2024Antibody-drug Conjugates Research, Reviewadc research, antibody drug conjugatesbioadc

The cure of cancer is not the only goal on the table and the very best are antibody-drug conjugates. These innovative drugs combine monoclonal antibodies with cytotoxic chemotherapies to deliver highly targetedRead More…

12Sep/24

Fresh Game Plan for Developing Antibacterial Conjugates

September 12, 2024Antibody-drug Conjugates ResearchAntibacterial Conjugatesbioadc

Bacterial infections are one of the most serious threats to human health, causing millions of deaths worldwide every year. However, due to the emergence of bacterial resistance, the antibacterial activity of manyRead More…

24Aug/24

Crafting Anti-nuclear “Missile” Therapy With Antibody-drug Conjugates

August 24, 2024ReviewANADC, Antibody-oligonucleotide Conjugatesbioadc

In a new study, researchers from Yale School of Medicine hide tumor-fighting antibodies from cancer by disguising them in molecules that cancers use to nourish tumor growth, based on a new therapyRead More…

23Jul/24

What’s New About Endometrial Cancer? An ADC Beyond Anticipation!

July 23, 2024NewsADC Therapy, Endometrial Cancerbioadc

The highly anticipated 115th American Association for Cancer Research (AACR 2024) Annual Meeting opened in San Diego, USA. As the focus of the cancer research community, scientists, clinicians, and cancer researchers fromRead More…

21Jun/24

Nature’s Breakthrough: ADCs and Base Editing Transform Blood Disease Treatment

June 21, 2024ReviewBlood Disease ADC, CD45-targeted Therapybioadc

Researchers from the University of Basel in Switzerland published a research paper titled “Selective haematological cancer eradication with preserved haematopoiesis” in the journal Nature. The entire hematopoietic system can be reconstructed byRead More…

14May/24

ADCs in Cancer Therapy: Innovations, Challenges, and Outlooks

May 14, 2024ReviewADC, ADC resistance, AJICAP technology, Cancer Therapybioadc

The emergence of antibody-drug conjugates (ADCs) as a potential cancer treatment pathway has attracted a great deal of attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drugRead More…

21Apr/24

It’s High Time For Next Generation Adcs To Set Out: 5 Ways To Go – Part II

April 21, 2024ReviewDAC, ISAC, PDCbioadc

Conditionally activated antibody prodrug conjugate (PDC) Traditional ADCs not only target receptors expressed on tumor cells but also those on certain healthy tissues, leading to inevitable off-tumor toxicity. Probody Drug Conjugates (PDCs)Read More…

19Apr/24

It’s High Time For Next Generation Adcs To Set Out: 5 Ways To Go

April 19, 2024ReviewADC design, Next Generation ADCbioadc

Antibody-drug conjugates (ADCs) represent a highly promising approach to cancer treatment, capable of selectively delivering highly cytotoxic payloads to tumors. However, ADCs are currently facing a series of challenges, including resistance, tumorRead More…

22Mar/24

Optimization Strategies for ADC and Related Bioanalytical Methods

March 22, 2024UncategorizedADC Bioanalysisbioadc

The emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules,Read More…

18Mar/24

How to Screen an ADC Payload?

March 18, 2024ReviewADC payloadbioadc

Introduction of the Camptothecin Derivative Payload Camptothecin was first isolated from camptothecin stems in 1966 by Wall et al., mainly in the form of topological isomerase (topoI). In order to inhibit theRead More…